{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002707","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.132339+00:00","generated_at":"2026-06-07T02:22:59.496691+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dianthus expects ~$173M cash at year-end 2023; to present at JPM conference","bullets":["Preliminary unaudited cash, equivalents, and short-term investments of ~$173M as of Dec 31, 2023.","Audited FY2023 financials not yet available; actual results may differ materially.","CEO Marino Garcia to present at 42nd Annual J.P. Morgan Healthcare Conference on Jan 11, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002707","json":"https://secwatch.observer/filing/0000950170-24-002707.json","markdown":"https://secwatch.observer/filing/0000950170-24-002707.md","text":"https://secwatch.observer/filing/0000950170-24-002707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/0000950170-24-002707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:22:59.496691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}